An Update on Reported Variants in the Skeletal Muscle α ‐Actin ( ACTA1 ) Gene
Human Mutation · 2024
DOI: 10.1155/2024/6496088 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Mutation, 2024. Verfasst von Joshua S Clayton und 8 weiteren Autor:innen. Beteiligte Einrichtung: Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia, Australia. Hauptthemen laut MEDLINE: Actins, Muscle, Skeletal, Mutation, Genetic Variation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, University of Western Australia, French Muscular Dystrophy Association.
Abstract (Originalsprache)
The ACTA1 gene encodes skeletal muscle alpha‐actin, which forms the core of the sarcomeric thin filament in adult skeletal muscle. ACTA1 represents one of six highly conserved actin proteins that have all been associated with human disease. The first 15 pathogenic variants in ACTA1 were reported in 1999, which expanded to 177 in 2009. Here, we update on the now 607 total variants reported in LOVD, HGMD, and ClinVar, which includes 343 reported pathogenic/likely pathogenic (P/LP) variants. We also provide suggested ACTA1 ‐specific modifications to ACMG variant interpretation guidelines based on our analysis of known variants, gnomAD reports, and pathogenicity in other actin isoforms. Using these criteria, we report a total of 447 P/LP ACTA1 variants. From a clinical perspective, the number of reported ACTA1 disease phenotypes has grown from five to 20, albeit with some overlap. The vast majority (74%) of ACTA1 variants cause nemaline myopathy (NEM), but there are increasing numbers that cause cardiomyopathy and novel phenotypes such as distal myopathy. We highlight challenges associated with identifying genotype–phenotype correlations for ACTA1 . Finally, we summarize key animal models and review the current state of preclinical treatments for ACTA1 disease. This update provides important resources and recommendations for the study and interpretation of ACTA1 variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia, Australia.
- Centre for Medical Research, University of Western Australia, QEII Medical Centre, Nedlands, Western Australia, Australia.
- Folkhälsan Research Center, Department of Medical and Clinical Genetics, Medicum, University of Helsinki, Helsinki, Finland.
- Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Victoria, Australia.
- Department of Pediatrics, University of Melbourne, The Royal Children's Hospital, Melbourne, Victoria, Australia.
ORCID-Profile: Joshua S Clayton, Mridul Johari, Nigel G Laing
Förderung
- Medical Research Council
- University of Western Australia
- French Muscular Dystrophy Association
- Association Française contre les Myopathies
- Raine Medical Research Foundation
- National Health and Medical Research Council
- Stan Perron Charitable Foundation
Zitieren
APA
Clayton, J. S., Johari, M., Taylor, R. L., Dofash, L., Allan, G., Monahan, G., Houweling, P. J., Ravenscroft, G., & Laing, N. G. (2024). An Update on Reported Variants in the Skeletal Muscle α ‐Actin ( ACTA1 ) Gene. Human Mutation. https://doi.org/10.1155/2024/6496088
Vancouver
Clayton JS, Johari M, Taylor RL, Dofash L, Allan G, Monahan G, et al. An Update on Reported Variants in the Skeletal Muscle α ‐Actin ( ACTA1 ) Gene. Human Mutation. 2024. doi:10.1155/2024/6496088
BibTeX
@article{Clayton2024,
author = {Clayton, Joshua S and Johari, Mridul and Taylor, Rhonda L and Dofash, Lein and Allan, Georgina and Monahan, Gavin and Houweling, Peter J and Ravenscroft, Gianina and Laing, Nigel G},
title = {An Update on Reported Variants in the Skeletal Muscle α ‐Actin ( ACTA1 ) Gene},
journal = {Human Mutation},
year = {2024},
doi = {10.1155/2024/6496088}
}
EUVIMED